Full Committee Hearing
“Valeant Pharmaceuticals' Business Model: the Repercussions for Patients and the Health Care System”
Date:
Time:
03:30pm
Location:
Hart, Room 216
Panel I
-
Berna Heyman
Wilson Disease patient, and retired Associate Dean of LibrariesWilliam & Mary -
Dr. Frederick K. Askari, M.D. PhD
Associate Professor, and Director, Wilson Disease Center of ExcellenceUniversity of Michigan Health System -
Dr. Richard Fogel M.D., FACC, FHRS
Chief Clinical OfficerSt. Vincent
Panel II
-
William A. Ackman
Founder and Chief Executive Officer, Director,Pershing Square Capitol Management LP,, Valeant Pharmaceuticals International, Inc., -
J. Michael Pearson
Chief Executive OfficerValeant Pharmaceuticals International, Inc -
Howard Schiller
Director, former Chief Financial Officer, and former Interim Chief Executive OfficerValeant Pharmaceuticals International, Inc.,
